Pediatric Extreme Thrombocytosis: Etiology, Management, and Outcomes

Area of Science:

• Pediatric Hematology
• Thrombosis Research
• Clinical Pediatrics

Background:

• Extreme thrombocytosis (EXT) is defined as a platelet count exceeding 1000×10⁹/L.
• Understanding the causes and consequences of pediatric EXT is crucial for patient management.

Purpose of the Study:

• To investigate the etiology, management strategies, and clinical outcomes of pediatric patients diagnosed with extreme thrombocytosis.
• To specifically assess the incidence and contributing factors of thrombotic complications in this population.

Main Methods:

• A retrospective analysis of electronic medical records was conducted over a 5-year period at a tertiary care center.
• Data collected included patient demographics, clinical features, laboratory results, underlying causes of EXT, and follow-up information on platelet counts and thrombotic events.

Main Results:

• The study identified 204 pediatric patients with EXT, with 98% having secondary thrombocytosis linked to infections or inflammatory conditions.
• EXT was most common in infants (median age 1.3 years).
• Thrombotic events occurred in 4.9% of cases, often associated with central venous lines or other risk factors, not solely the high platelet count.

Conclusions:

• Secondary extreme thrombocytosis in children is frequently linked to infections and can persist for up to two months.
• While EXT itself may not be a major thrombotic risk factor, it can contribute to risk in patients with additional predisposing conditions.
• Further research, including prospective studies, is needed to fully understand thrombotic risks and the role of antithrombotic prophylaxis in pediatric EXT.